嚢胞性線維症治療市場：規模、世界市場の予測（2023年～2028年）、業界動向、シェア、成長、インフレの影響、企業分析

世界の嚢胞性線維症治療の市場規模は、2022年に108億6,000万米ドルとなりました。同市場は今後、14.40%のCAGRで拡大し、2028年までに243億5,000万米ドルに達すると予測されています。

当レポートでは、世界の嚢胞性線維症治療市場について調査し、市場の概要とともに、投与経路別、治療法別、検査タイプ別、流通チャネル別、薬剤クラス別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査と調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因
• 課題

第5章 世界の嚢胞性線維症治療市場

第6章 市場シェア-世界の嚢胞性線維症治療市場

• 投与経路別
• 治療法別
• 検査タイプ別
• 流通チャネル別
• 薬剤クラス別
• 地域別

第7章 投与経路別-世界の嚢胞性線維症治療市場

• 経口
• 吸入

第8章 治療法別-世界の嚢胞性線維症治療市場

• 投薬
• 機器
• その他

第9章 検査タイプ別-世界の嚢胞性線維症治療市場

• 肺機能検査
• 発汗検査
• IRT検査
• 糞便検査
• 遺伝子検査

第10章 流通チャネル別-世界の嚢胞性線維症治療市場

• 病院
• 小売薬局
• その他

第11章 薬剤クラス別-世界の嚢胞性線維症治療市場

• 膵臓酵素補充薬
• 粘液溶解薬
• 気管支拡張薬
• CFTR調整薬

第12章 地域別-世界の嚢胞性線維症治療市場

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第13章 企業の洞察

• Vertex Pharmaceuticals
• Abbvie Inc.
• Novartis Ag
• Gilead Sciences
• Viatris INC
• Pfizer
• Astrazeneca

List of Figures

• Figure-01: Global - Cystic Fibrosis Therapeutics Market (Billion US$), 2016 - 2022
• Figure-02: Global - Forecast for Cystic Fibrosis Therapeutics Market (Billion US$), 2023 - 2028
• Figure-03: Route of Administration - Oral Market (Million US$), 2016 - 2022
• Figure-04: Route of Administration - Forecast for Oral Market (Million US$), 2023 - 2028
• Figure-05: Route of Administration - Inhale Market (Million US$), 2016 - 2022
• Figure-06: Route of Administration - Forecast for Inhale Market (Million US$), 2023 - 2028
• Figure-07: Treatment Method - Medication Market (Million US$), 2016 - 2022
• Figure-08: Treatment Method - Forecast for Medication Market (Million US$), 2023 - 2028
• Figure-09: Treatment Method - Devices Market (Million US$), 2016 - 2022
• Figure-10: Treatment Method - Forecast for Devices Market (Million US$), 2023 - 2028
• Figure-11: Treatment Method - Other Treatment Market (Million US$), 2016 - 2022
• Figure-12: Treatment Method - Forecast for Other Treatment Market (Million US$), 2023 - 2028
• Figure-13: Test Type - Pulmonary Function Test Market (Million US$), 2016 - 2022
• Figure-14: Test Type - Forecast for Pulmonary Function Test Market (Million US$), 2023 - 2028
• Figure-15: Test Type - Sweat Test Market (Million US$), 2016 - 2022
• Figure-16: Test Type - Forecast for Sweat Test Market (Million US$), 2023 - 2028
• Figure-17: Test Type - IRT Test Market (Million US$), 2016 - 2022
• Figure-18: Test Type - Forecast for IRT Test Market (Million US$), 2023 - 2028
• Figure-19: Test Type - Fecal Tests Market (Million US$), 2016 - 2022
• Figure-20: Test Type - Forecast for Fecal Tests Market (Million US$), 2023 - 2028
• Figure-21: Test Type - Genetic Tests Market (Million US$), 2016 - 2022
• Figure-22: Test Type - Forecast for Genetic Tests Market (Million US$), 2023 - 2028
• Figure-23: Distribution Channels - Hospitals Market (Million US$), 2016 - 2022
• Figure-24: Distribution Channels - Forecast for Hospitals Market (Million US$), 2023 - 2028
• Figure-25: Distribution Channels - Retail Pharmacies Market (Million US$), 2016 - 2022
• Figure-26: Distribution Channels - Forecast for Retail Pharmacies Market (Million US$), 2023 - 2028
• Figure-27: Distribution Channels - Others Market (Million US$), 2016 - 2022
• Figure-28: Distribution Channels - Forecast for Others Market (Million US$), 2023 - 2028
• Figure-29: Drug Class - Pancreatic Enzyme Supplements Drug Market (Million US$), 2016 - 2022
• Figure-30: Drug Class - Forecast for Pancreatic Enzyme Supplements Drug Market (Million US$), 2023 - 2028
• Figure-31: Drug Class - Mucolytics Drug Market (Million US$), 2016 - 2022
• Figure-32: Drug Class - Forecast for Mucolytics Drug Market (Million US$), 2023 - 2028
• Figure-33: Drug Class - Bronchodilators Drug Market (Million US$), 2016 - 2022
• Figure-34: Drug Class - Forecast for Bronchodilators Drug Market (Million US$), 2023 - 2028
• Figure-35: Drug Class - CFTR Modulators Drug Market (Million US$), 2016 - 2022
• Figure-36: Drug Class - Forecast for CFTR Modulators Drug Market (Million US$), 2023 - 2028
• Figure-37: North America - Cystic Fibrosis Therapeutics Market (Million US$), 2016 - 2022
• Figure-38: North America - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 - 2028
• Figure-39: Europe - Cystic Fibrosis Therapeutics Market (Million US$), 2016 - 2022
• Figure-40: Europe - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 - 2028
• Figure-41: Asia Pacific - Cystic Fibrosis Therapeutics Market (Million US$), 2016 - 2022
• Figure-42: Asia Pacific - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 - 2028
• Figure-43: Latin America - Cystic Fibrosis Therapeutics Market (Million US$), 2016 - 2022
• Figure-44: Latin America - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 - 2028
• Figure-45: Middle East & Africa - Cystic Fibrosis Therapeutics Market (Million US$), 2016 - 2022
• Figure-46: Middle East & Africa - Forecast for Cystic Fibrosis Therapeutics Market (Million US$), 2023 - 2028
• Figure-47: Vertex Pharmaceuticals - Global Revenue (Billion US$), 2016 - 2022
• Figure-48: Vertex Pharmaceuticals - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-49: Abbvie Inc. - Global Revenue (Billion US$), 2016 - 2022
• Figure-50: Abbvie Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-51: Novartis Ag - Global Revenue (Billion US$), 2016 - 2022
• Figure-52: Novartis Ag - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-53: Gilead Sciences - Global Revenue (Billion US$), 2016 - 2022
• Figure-54: Gilead Sciences - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-55: Viatris INC - Global Revenue (Billion US$), 2016 - 2022
• Figure-56: Viatris INC - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-57: Pfizer - Global Revenue (Billion US$), 2016 - 2022
• Figure-58: Pfizer - Forecast for Global Revenue (Billion US$), 2023 - 2028
• Figure-59: Astrazeneca - Global Revenue (Billion US$), 2016 - 2022
• Figure-60: Astrazeneca - Forecast for Global Revenue (Billion US$), 2023 - 2028

List of Tables

• Table-01: Global - Cystic Fibrosis Therapeutics Market Share by Route of Administration (Percent), 2016 - 2022
• Table-02: Global - Forecast for Cystic Fibrosis Therapeutics Market Share by Route of Administration (Percent), 2023 - 2028
• Table-03: Global - Cystic Fibrosis Therapeutics Market Share by Treatment Method (Percent), 2016 - 2022
• Table-04: Global - Forecast for Cystic Fibrosis Therapeutics Market Share by Treatment Method (Percent), 2023 - 2028
• Table-05: Global - Cystic Fibrosis Therapeutics Market Share by Test Type (Percent), 2016 - 2022
• Table-06: Global - Forecast for Cystic Fibrosis Therapeutics Market Share by Test Type (Percent), 2023 - 2028
• Table-07: Global - Cystic Fibrosis Therapeutics Market Share by Distribution Channels (Percent), 2016 - 2022
• Table-08: Global - Forecast for Cystic Fibrosis Therapeutics Market Share by Distribution Channels (Percent), 2023 - 2028
• Table-09: Global - Cystic Fibrosis Therapeutics Market Share by Drug Class (Percent), 2016 - 2022
• Table-10: Global - Forecast for Cystic Fibrosis Therapeutics Market Share by Drug Class (Percent), 2023 - 2028
• Table-11: Global - Cystic Fibrosis Therapeutics Market Share by Region (Percent), 2016 - 2022
• Table-12: Global - Forecast for Cystic Fibrosis Therapeutics Market Share by Regions(Percent), 2023 - 2028

Global Cystic Fibrosis Market will reach US$ 24.35 Billion by 2028 according to Renub Research. Cystic Fibrosis is an ongoing genetic disease that affects the lungs and other body systems (Pancreas, Liver, and Kidney) and for which there is currently no cure. It mainly affects the digestive and respiratory systems in children and young adults. About half of the population with cystic fibrosis will live past 40. It can cause problems with digestion and breathing from childhood age.

Over a decade, the lungs become increasingly damaged and may eventually stop working correctly. The primary target organs in cystic fibrosis are the sweat glands, the lungs, and the gastrointestinal tract, particularly the pancreas. Although clinically the least serious problem, increased sodium and chloride concentration in sweat is the undisputed hallmark of cystic fibrosis. The main symptoms of cystic fibrosis include chest infections, difficulty putting on weight, wet-sounding coughs, and others. Physical therapy is used to treat cystic fibrosis, which helps reduce mucus from the lungs, Provide complete nutrition, etc.

The outlook for cystic fibrosis has improved considerably in recent five years due to advancements in RD of treatment, although most people with cystic fibrosis will have shorter-than-average life assurance. According to Cystic Fibrosis Patient Registry, more than 30,000 people are currently suffering from this condition in the U.S., while more than 70,000 people are suffering from Cystic Fibrosis across the globe. In addition to this, more than approximately 1000 new cases of the disease are diagnosed every year.

Worldwide Cystic Fibrosis Market is expected to grow at a CAGR of 14.40% throughout the Forecast Period.

Rising spending on R&D research and other technological advancements in these therapeutic areas will open a new source of growth for industry participants. However, the higher cost of therapy, and several adverse effects of currently available drugs, such as liver problems, upper respiratory tract infection, chest pain, and increased blood pressure, among others, will restrain the industry growth. The Global Cystic Fibrosis industry was valued at US$ 10.86 Billion in 2022.

By Route of Administration: Inhale market will capture maximum share in the forecast Period

Based on the Route of Administration, The Global Cystic Fibrosis market has been divided into two types oral and inhaled. The Inhale holds significant share due to their use leading to high drug levels within the airways, with lean systemic effects, and High-quality devices providing safe and convenient antibiotic and mucolytic therapy for individuals with Cystic Fibrosis dominate the market.

Medication Treatment Method holds Largest Market

Based on Treatment, Medication captured the largest share during the forecast period due to antibiotics to prevent and treat chest infections, to make the mucus easier to cough up, the lungs thinner, and medicines to reduce inflammation and widen the airways. In addition, other factors such as rising demand and awareness about advance help stimulate the industry's expansion and significantly affect market share. The market has been categorized into Medication, Devices, and Other Treatments. Devices also hold the significant market revenue as the most commonly used pieces of equipment for CF treatments are compressors, nebulizers, and airway clearance devices. These are readily available in the market and convenient for patients.

By Test Type: Pulmonary Function Test Type holds the Significant Market

On the Test Type segment, the Global Cystic Fibrosis Therapeutics Market has been differentiated into Pulmonary Function, Sweat, IRT, Fecal, and Genetic. The Pulmonary Function Test holds the most significant revenue in 2022 due to the tests measuring lung volume, capacity, rates of flow, and gas exchange. This information can help healthcare providers diagnose and decide the treatment of certain lung disorders has significantly dominated the segment.

By Distribution Channels: Hospitals holds the Maximum Revenue

By Distribution Channels, Hospitals hold the maximum revenue due to the growing demand for the disease and the need for the right diagnosis and follow-up treatments under medical supervision. This leads to an increase in patient hospital visits, moving the growth of the hospital segment. Moreover, earnings generated by hospital pharmacies are proportionately high because infected people commonly visit nearby hospitals for doctor's prescription medicines and appointments. Therefore, the market is segmented into Hospitals, Retail Pharmacies, and Others.

CFTR Modulators Drug Class will gain the maximum revenue in upcoming years

Subjected to drug class, the Global Cystic Fibrosis industry has been grouped into Pancreatic Enzyme Supplements Drug, Mucolytic Drugs, Bronchodilators Drug, and CFTR Modulators Drug. The CFTR Modulators Drug holds the maximum revenue because CFTR modulator drugs are novel-specialized therapies that enhance the functional expression of CFTR mutants and have been approved for clinical use for individuals with specific CF genotypes. Highly effective CFTR modulator drugs are expected to modify the disease course for most individuals with CF profoundly. In addition, advanced experimental approaches have been established to accelerate the development of novel modulators, effectively boosting the Cystic Fibrosis Therapeutics Market.

North America will capture the maximum market in forecast period

By Region, the Global Cystic Fibrosis Market has been divided into North America, Latin America, Europe, Asia Pacific, and Others. However, North America dominated the market share due to demand from the increasing occurrence of cystic fibrosis and the accessibility of several treatment options in the Region. Moreover, rising government initiative such as increasing funding for innovations and R&D projects on cystic fibrosis drug drives the industry revenue. For instance, the North American Cystic Fibrosis Conference (NACFC gives an educational forum for cystic fibrosis specialists to share developments in R&D related to cystic fibrosis therapeutics.

In addition, other factors, such as the presence of foremost market leaders, reimbursements, and well-established healthcare infrastructure, will propel the North American market demand over the forecast timeframe.

Key Company Insight

Some of the primary key players in the Global Cystic Fibrosis Therapeutics Market include Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer, and AstraZeneca.

In August 2021, Sanofi signed an agreement to acquire Translate Bio, all outstanding shares, for $3.2 billion. Translate Bio has cystic fibrosis and other rare pulmonary diseases in his pipeline.

In Nov 2021, Eloxx Pharmaceuticals announced the monotherapy arms product pipeline of its Phase 2 clinical trial of ELX-02 in cystic fibrosis (CF) Class 1.

Renub Research report titled "Cystic Fibrosis Therapeutics Market, Global Forecast by Route of Administration (Oral and Inhale), Treatment (Medication, Devices, Other Treatment), Test Type (Plumonary Function, Sweat Colories, IRT Test, Faceal Tests and Genetic Tests), Distribution (Hospital, Retail Pharmacies and Others), Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators and CFTR Modulators) Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Vertex Pharmaceuticals, Abbvie Inc., Novartis Ag, Gilead Sciences, Viatris INC, Pfizer and Astrazeneca,)" Provides a detailed analysis of Cystic Fibrosis Therapeutics Market.

Route of Administration - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 2 Viewpoints

1. Oral

2. Inhale

Treatment - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints

1. Medication

2. Devices

3. Other Treatment

Test Type - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints

1. Plumonary Function

2. Sweat Calories

3. IRT Test

4. Faceal Tests

5. Genetic Tests

Distribution - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 3 Viewpoints

1. Hospital

2. Retail Pharmacies

3. Others

Drug Class - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 4 Viewpoints

1. Pancreatic Enzyme Supplements

2. Mucolytics

3. Bronchodilators

4. CFTR Modulators

Region - Cystic Fibrosis Therapeutics Market Analysis have been Covered from 5 Viewpoints

1. North America

2. Europe

3. Asia Pacific

4. Latin America

5. Middle East & Africa

All companies have been covered from 3 viewpoints:

• Overviews
• Recent Developments
• Revenues

Company

1. Vertex Pharmaceuticals

2. Abbvie Inc.

3. Novartis Ag

4. Gilead Sciences

5. Viatris INC

6. Pfizer

7. Astrazeneca

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Global Cystic Fibrosis Therapeutics Market

6. Market Share - Global Cystic Fibrosis Therapeutics Market

• 6.1 By Route of Administration
• 6.2 By Treatment Method
• 6.3 By Test Type
• 6.4 By Distribution Channels
• 6.5 By Drug Class
• 6.6 By Region

7. Route of Administration - Global Cystic Fibrosis Therapeutics Market

• 7.1 Oral
• 7.2 Inhale

8. Treatment Method - Global Cystic Fibrosis Therapeutics Market

• 8.1 Medication
• 8.2 Devices
• 8.3 Other Treatment

9. Test Type - Global Cystic Fibrosis Therapeutics Market

• 9.1 Pulmonary Function Test
• 9.2 Sweat Test
• 9.3 IRT Test
• 9.4 Fecal Tests
• 9.5 Genetic Tests

10. Distribution Channels - Global Cystic Fibrosis Therapeutics Market

• 10.1 Hospitals
• 10.2 Retail Pharmacies
• 10.3 Others

11. Drug Class - Global Cystic Fibrosis Therapeutics Market

• 11.1 Pancreatic Enzyme Supplements Drug
• 11.2 Mucolytics Drug
• 11.3 Bronchodilators Drug
• 11.4 CFTR Modulators Drug

12. Region - Global Cystic Fibrosis Therapeutics Market

• 12.1 North America
• 12.2 Europe
• 12.3 Asia Pacific
• 12.4 Latin America
• 12.5 Middle East & Africa

13. Company Insights

• 13.1 Vertex Pharmaceuticals
  • 13.1.1 Overview
  • 13.1.2 Recent Development
  • 13.1.3 Revenue
• 13.2 Abbvie Inc.
  • 13.2.1 Overview
  • 13.2.2 Recent Development
  • 13.2.3 Revenue
• 13.3 Novartis Ag
  • 13.3.1 Overview
  • 13.3.2 Recent Development
  • 13.3.3 Revenue
• 13.4 Gilead Sciences
  • 13.4.1 Overview
  • 13.4.2 Recent Development
  • 13.4.3 Revenue
• 13.5 Viatris INC
  • 13.5.1 Overview
  • 13.5.2 Recent Development
  • 13.5.3 Revenue
• 13.6 Pfizer
  • 13.6.1 Overview
  • 13.6.2 Recent Development
  • 13.6.3 Revenue
• 13.7 Astrazeneca
  • 13.7.1 Overview
  • 13.7.2 Recent Development
  • 13.7.3 Revenue